Physician profile
Janie Peters
NPI 1700274065
$1,415.59
in general payments reported to CMS, 2019-2025
20 companies · $488 in 2025
The $488 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $79.47 · 2022: $84.76 · 2023: $263 · 2024: $500 · 2025: $488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,172 · Education: $79.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,171.86 |
| Education | $79.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $356.85 | 2023-2025 | Austedo Xr, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $246.85 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $233.88 | 2023-2024 | Nuedexta, Rexulti |
| Ucb, INC. | $123.35 | 2024 | Nayzilam |
| Vanda Pharmaceuticals INC. | $95.38 | 2025 | Fanapt |
| Axsome Therapeutics, INC. | $79.73 | 2024 | Auvelity |
| Novo Nordisk INC | $34.81 | 2021 | |
| Lilly USA, LLC | $30.61 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.57 | 2022 | |
| Coloplast Corp | $24.89 | 2024 | |
| Kci USA, INC. | $22.51 | 2023 | Prevena, Activ.A.C., Kerramax Care |
| Ardelyx, INC. | $21.26 | 2024 | Ibsrela |
| Kerecis Limited | $20.04 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Biogen, INC. | $18.16 | 2022 | |
| Abbvie INC. | $14.87 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hydrofera LLC | $14.31 | 2024 | Hydrofera Blue |
| Astrazeneca Pharmaceuticals LP | $14.24 | 2021 | |
| Sumitomo Pharma America, INC. | $12.31 | 2023 | Aptiom |
| Amgen INC. | $12.10 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $11.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janie Peters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.